Speaker: Fabienne Thibault, Paris/FR
Moderator: Daly Avendano, Monterrey/MX
Date: Thursday, April 15, 2021
Time: 17:00-18:00 CEST

Speaker: Jonathan James, Nottingham/UK
Moderator: Mirjam Wielema, Groningen/NL
Date: Wednesday, May 12, 2021
Time: 17:00-18:00 CEST

Speaker: Eva M. Fallenberg, Munich/DE
Moderator: Federica Leone, Milan/IT
Date: Wednesday, May 26, 2021
Time: 17:00-18:00 CEST

Speaker: Daniela Bernardi, Milan/IT
Moderator: Lucia Grana, Lugo/ES
Date: Thursday, February 25, 2021
Time: 17:30-18:30 CET

Recording
The recording will be available after 2-3 weeks.

Speaker: Sophia Zackrisson, Malmö/SE
Moderator: Heike Preibsch, Tübingen/DE
Date: Tuesday, Feburary 9, 2021
Time: 17:00-18:00 CET

What can you expect from this webinar?
This lecture will cover the basics and advances of digital breast tomosynthesis, DBT, and its role in breast cancer screening and clinical breast imaging. Scientific background data will be presented, and cases will be used to illustrate pearls and pitfalls with DBT in different situations.

What can you learn during this webinar?
– the technique behind digital breast tomosyntesis, strengths and limitations
– the current scientific evidence and recommendations for use of DBT in screening
– clinical situations where DBT might be useful

Recording
The recording will be available after 2-3 weeks.

Speaker: Francesca Caumo, Verona/IT
Moderator: Elisabetta Giannotti, Nottingham/UK
Date: Wednesday, January 27, 2021
Time: 17:00-18:00 CET

What can you expect from this webinar?
Decide to undergo screening is an individual choice. The main questions are: how large the benefit of screening is in terms of reduced breast cancer mortality and how substantial the harm is in terms of interval cancers (defined as a cancer diagnosed after a negative mammographic screen and before the next routine screen), reduction of sensibility of mammography in dense breast and overdiagnosis, which is defined as the detection of cancers with screening which would not have become clinically apparent in the woman’s lifetime in the absence of screening.

There are two strategies to improve the effect of a screening program: find a better first level test- Automated Breast Ultrasound System (ABUS)-Magnetic Resonance Imaging (MRI)-Digital Breast Tomosynthesis (DBT)-Hand-Held Ultrasound (HHUS) or try the way to overcoming effect of density and make a better risk classification to have different screening strategies including other imaging modalities, in addition to mammography, that might improve early detection of breast cancer.
International strategy (Wisdom Study; Dense Study, MyPeBs) is thinking about tailored screening modifying interval screen and using other modality.

The objective of the webinar is to describe this experience and show our project: RiBS (RiskBasedScreening)

Recording
Watch the webinar recording HERE

Speaker: Panagiotis Kapetas, Vienna/AT
Moderator: Mirjam Wielema, Groningen/NL
Date: Tuesday, June 9, 2020
Time: 18:00 CEST

What can you expect from this webinar?
MRI has the highest sensitivity for the identification of breast cancer among all imaging modalities. The increased implementation of breast MRI studies leads to the identification of a large number of additional lesions that necessitate further work-up. While some of these can be identified, characterized and/or biopsied through second-look ultrasound, a substantial number of these lesions are only evident in MRI and thus need to undergo an MRI-guided biopsy.
The aim of this webinar is to provide an insight into the management of breast lesions only visible on MRI. A thorough, focused second-look ultrasound examination is a prerequisite- after securing that the lesion has no sonographic correlate, an MRI-guided intervention is necessary. The procedure of MRI-guided biopsies and wire-localizations will be described. A thorough radiologic-pathologic correlation is extremely important, just like with any other image-guided intervention.

What can you learn during this webinar?
– Performance of second-look ultrasound
– Procedure of MRI-guided biopsies with different systems
– Pearls and pitfalls of MRI-guided biopsies
– Considerations on the congruence of the pathologic outcome
– Regulatory issues

Recording
Watch the webinar recording HERE

Speaker: Machteld Keupers, Leuven/BE
Moderator: Elisabetta Giannotti, Nottingham/UK
Date: Monday, May 4, 2020
Time: 17:00 CEST

What can you expect from this webinar?
Breast cancer is the most frequent cancer in women in Europe. Mammography is the only tool used in population based breast cancer screening in Europe that has proven to save lives while reducing aggressive treatment by detecting cancer at an earlier stage. A screening programme can only achieve those benefits if there is quality control, both for the screening modality as well as for all further diagnostic procedures and treatment.
This webinar aims to provide an overview of the literature and guidelines for breast cancer screening with MRI. Women at high risk for breast cancer due to genetic factors can be offered additional screening with ultrasound and MRI outside general population screening programmes. For women with average risk but with dense breasts, screening with MRI is not yet recommended by the European Guidelines. In order to meet the high quality standards of a good screening programme, several considerations have to be made.

What can you learn during this webinar?
– European guidelines on breast cancer screening and subsequent diagnosis.
– Criteria for quality control in breast cancer screening.
– The (dis)advantages of breast MRI in screening in a high risk population and in general population.
– The considerations regarding implementation of MRI in breast cancer screening for dense breasts.
– Case-based discussion of the pros and cons of breast MRI in screening.

Recording
Watch the webinar recording HERE

Speaker: Silvia Perez, Madrid/ES
Moderator: Daly Avendano, Monterrey/MX
Date: Tuesday, April 14, 2020
Time: 17:00 CEST

What can you expect from this webinar?
Nowadays, the treatment of breast cancer includes not only a safe treatment with the objective of having free margins, but also recover the shape of the breast. Besides, the augmented mammoplasty for esthetic reasons is more and more common. When the augmented mammoplasty is performed for reconstructive reasons is called heterologous reconstruction. The heterologous reconstruction uses external material to reconstruct the breast. The most frequent materials employed are the implants.
In this webinar we will discuss about the types of implants and also about the normal, abnormal appearance of them on MRI and possible complications.

What will you learn during this webinar?
– To know the different types of implants.
– To know the MRI protocol for the study of the implants.
– To know the normal appearance of the implants.
– To know the abnormal appearance of the implants.
– To know the signs of intracapsular rupture.
– To know the signs of extracapsular rupture.
– To know possible complications
– To know the possibility of recurrence

Recording
Watch the webinar recording HERE

Speaker: Matthias Dietzel, Erlangen/DE
Moderator: Hajer Jarraya, Lille/FR
Date: Tuesday, March 24, 2020
Time: 17:30 CEST

Recording
Watch the webinar recording HERE

Speakers: Pascal Baltzer, Vienna/AT; Paola Clauser, Vienna/AT
Date: Wednesday, February 19, 2020
Time: 18:00 CET

What can you expect from this webinar?
Breast MRI is commonly used in cases with equivocal or inconclusive findings on mammography, tomosynthesis and ultrasound. Breast MRI, though, might cause a non negligible number of additional biopsies and follow up for benign lesions. Thus, MRI is considered by many a problem maker, rather than a problem solver.
The literature and guidelines that discuss the topic will be presented.

The webinar will focus on:
– Defining problem solving breast MRI;
– Discussing the pros and contra of problem solving breast MRI;
– Giving example through cases on when MRI should (or should not) be used as a problem solving method.

Recording
Watch the webinar recording HERE

Speaker: Monique Dorrius, Groningen/NL
Wednesday, January 22, 2020
17:30 CET

What can I expect from this webinar?
Dynamic contrast enhanced magnetic resonance imaging is widely used in breast cancer imaging. From all breast imaging modalities MRI has the highest negative predictive value (> 98%), and therefore breast cancer can be exclude safely in case of a negative scan. However when during the assessment of DCE MRI enhanced breast lesions are found, most of the time differentiation between benign and malignant breast lesions is difficult. This is because of the considerable overlap in enhancement patterns between benign and malignant breast lesions. In general practice there is need for a second look ultrasound and probably an invasive procedure, like a core needle biopsy. In most of the cases the anxiety of the woman and the biopsy itself is unnecessary in benign lesions. To overcome the problem of equivocal enhanced breast lesions, the question arise whether Diffusion Weighted Imaging can play a role. If so, when and how should DWI be used in the diagnostic work up? What is an “optimal” DWI breast protocol? The answer on these questions will be addressed in this webinar. Furthermore, the effect of b value on the accuracy of breast DWI and the diagnostic performance of the region of interest methods are highlighted subjects. In the end there will be short comparison between the role of DWI and MR spectroscopy in the diagnostic workflow of breast lesions.

What will I learn during this webinar?
– The role of Dynamic Contrast Enhanced Magnetic Resonance Imaging in breast cancer imaging
– When to use Diffusion Weighted Imaging (DWI) in breast cancer imaging
– How to use Diffusion Weighted Imaging in breast cancer imaging; The “optimal” DWI protocol
– The effect of b-value on the diagnostic accuracy of breast DWI
– The diagnostic performance of different region of interest methods in DWI
– DWI versus MR spectroscopy

Recording
Watch the webinar recording HERE

Speaker: Katja Pinker-Domenig, New York/US; Vienna/AT
Thursday, December 12, 2019
17:00 CET

What can I expect from this webinar?
Magnetic resonance imaging (MRI) of the breast is an established non-invasive imaging technique with several indications including preoperative staging of breast cancer. In breast cancer patients MRI of the breast may be performed to assess lesion extent, detect satellite lesions as well as other cancers in the ipsi- or contralateral breast. This presentation aims to provide a comprehensive overview on the possible indications of preoperative MRI, to discuss the potential advantages and disadvantages of preoperative MRI and to highlight the importance of thorough pre-examination information about MRI of the breast to be provided to cancer patients.

Recording
Watch the webinar recording HERE

Speaker: Pascal Baltzer, Vienna/AT
Monday, November 4, 2019
17:30 CET

What can I expect from this webinar?
A comprehensive review of what a standard clinical protocol should contain. Practical tips and typical pitfalls will be addressed. The participant should be able to set up a multiparametric breast MRI protocol after having attended this webinar.

What will I learn during this webinar?

• The basic sequences a clinical breast MRI protocol should contain;
• Tips and tricks to achieve robust image quality;
• Practicalities regarding an optimized workflow including patient care and positioning, contrast injection and sequence timing.

Recording
Watch the webinar recording HERE

DISCUSSED ARTICLE: Supplemental MRI Screening for Women with Extremely Dense Breast Tissue
Bakker, M.F., de Lange, S.V., Pijnappel, R.M. et al., for the DENSE Trial Study Group. Supplemental MRI Screening for Women with Extremely Dense Breast Tissue. N Engl J Med 2019; 381:2091-2102. https://www.nejm.org/doi/full/10.1056/NEJMoa1903986

PRESENTER/MODERATOR: Mirjam Wielema, Groningen/NL
DISCUSSANTS: Pascal Baltzer, Vienna/AT; Matthias Dietzel, Erlangen/DE; Clemens Kaiser, Heidelberg/DE

DATE: Wednesday, December 9, 2020
TIME: 17:00 CET

RECORDING:
Watch the Journal Club recording HERE
Recordings are only available to EUSOBI Members in good standing!

DISCUSSED ARTICLE: International evaluation of an AI system for breast cancer screening
McKinney, S.M., Sieniek, M., Godbole, V. et al. International evaluation of an AI system for breast cancer screening. Nature 577, 89–94 (2020). https://doi.org/10.1038/s41586-019-1799-6

PRESENTER: Nina Pötsch, Vienna/AT
DISCUSSANTS: Magda Marcon, Zurich/CH & Anton Becker, US
MODERATOR: Maria Adele Marino, Messina/IT

DATE: Monday, November 9, 2020
TIME: 17:30 CET

RECORDING:
Watch the Journal Club recording HERE
Recordings are only available to EUSOBI Members in good standing!

DISCUSSED ARTICLE: Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic. Curigliano G, et al, Breast. 2020 Apr 16;52:8-16.

PRESENTER: Anna D’Angelo, Rome/IT
DISCUSSANTS: Valentina Iotti, Regio Emilia/IT; Joao Horvat, Sao Paulo/BR
MODERATOR: Thiemo van Nijnatten, Maastricht/NL

DATE: Tuesday, June 23, 2020
TIME: 19:00 CEST

RECORDING:
Watch the Journal Club recording HERE
Recordings are only available to EUSOBI Members in good standing!

October 2018 (ESR, Vienna) – Athens played host to the European Society of Breast Imaging (EUSOBI) Annual Scientific Meeting, which took place on 11-13 October and saw its highest level of participation since the society was founded. With over 900 in attendance, the congress is on the fast lane to become the universal leading meeting in breast imaging.

Held in a different location each year, this year’s meeting saw over 100 additional participants compared to last year’s congress in Berlin.

The annual meeting was organised in collaboration with the Hellenic Society of Breast Imaging and involved the active participation of many Greek radiologists, but also pathologists, breast surgeons, medical oncologists and radiation oncologists. These participants, as well as many other worldwide experts helped bring an exciting programme to audiences, with highlights including dedicated sessions on tomosynthesis in screening/diagnostic settings, artificial intelligence and evidence-based imaging, and advanced/multiparametric ultrasound. This year’s EUSOBI Gold Medal, an award introduced in 2014, was given to Professor Christiane K. Kuhl from Aachen/Germany.

Part of the meeting’s success can be attributed to its expanded programme. This year, EUSOBI extended the congress to 2.5 days, offering a variety of pre-congress courses. These courses included updates on case-based BI-RADS classification, interventional procedures and B3 lesions. In addition and for the first time, the EUSOBI Young Club Committee organised a post-congress special symposium dedicated to young radiologists with an interest in breast imaging and diagnostics.

EUSOBI Past-President, Professor Gábor Forrai from Budapest/Hungary, is delighted with the annual meeting’s growth over the course of his three-year presidency. ‘Each year, I am so happy to see more and more people taking an interest in breast imaging. The fact that they are willing to give their time to come teach, learn and share ideas with colleagues here in Athens is an impressive mark of how dedicated those working in this field are’. During the congress in Athens Doctor Julia Camps Herrero from Valencia/Spain took over the presidency for the next two years. She will be taking office at an exciting time for the society, with EUSOBI having just reached a milestone of serving over 1,000 members for the first time since it was founded.

The European Society of Radiology (ESR) would like to congratulate the European Society of Breast Imaging and the Hellenic Society of Breast Imaging for the success of the meeting and look forward to seeing more great things from EUSOBI in the future.

You can learn more about EUSOBI’s annual meeting here.

Thursday, September 22, 2016 (EUSOBI) – The European Society of Breast Imaging (EUSOBI) will hold its Annual Scientific Meeting in Paris, La Villette, in collaboration with the Society of Female Imaging – Société d’Imagerie de la Femme (SIFEM) on September 23–24, 2016. A breast magnetic resonance imaging (MRI) course for radiologists is also being held in advance on September 21–22.

Some 660 registered participants are expected to attend this year’s Annual Meeting, confirming a continuously increasing number of attendees over the years.

EUSOBI offers a balanced programme with cutting-edge science and good everyday practice. The Paris meeting will be a perfect opportunity to meet and exchange knowledge with experts and breast radiologists, as well as related companies from all over Europe and beyond.

The EUSOBI National Societies Network is made up of 29 countries. The first position paper from this large group of breast radiology societies will be published in European Radiology in October 2016, addressing the fundamental role of screening mammography for reducing the breast cancer mortality. EUSOBI unequivocally recommends all women to attend screening, according to their countries’ protocols.

This year, the 30th anniversary of contrast-enhanced breast MRI (1986–2016) will be celebrated with the EUSOBI Gold Medal Lecture delivered by Prof. Sylvia Heywang-Köbrunner, who was the first to report on this excellent diagnostic method in 1986. The Keynote Lecture will be delivered by Prof. Hedvig Hricak (Chairman of the Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, USA) on oncologic imaging in clinical decision making. The President of the U.S. Society of Breast Imaging, Prof. Elizabeth Morris (Chief of Breast Imaging at the Memorial Sloan-Kettering Cancer Center, New York, USA), will present the latest research and achievements in metastatic breast cancer.

The ‘Best way to screen’ session will tackle a hot topic as the debate on breast screening continues while the ‘Cutting edge’ and ‘B3 management’ sessions will include the latest scientific achievements. EUSOBI is currently focusing on breast MRI as this method already plays a major role in daily care, therapy planning and determining disease prognosis.

The EUSOBI Young Club will welcome its new active members at the special young scientists’ session, where the Young Investigator Award will be handed over and the best submitted poster abstracts will be presented.

EUSOBI will announce its new ‘5 points against breast cancer’ in Paris:

• In Europe, there are slightly different breast screening protocols in every country, but one statement is uniform: mammography saves lives and life quality – it can decrease breast cancer death by up to 40%.
• One in five breast cancers occur in women below 50, so screening should start before this age, at least at 45.
• 45% of breast cancers and related deaths occur in women at 65 and over. One in three breast cancers occur in women over 70, so screening should not stop at this age, but continue at least up to 75.
• If a woman has breast symptoms, the breast radiologist is the doctor to meet – he/she integrates all diagnostic techniques in order to give the most accurate information on breast health status e. g. cancer disease.
• The woman’s risk profile matters: personalised screening protocols may include ultrasound and/or MRI – but should always be interpreted together with mammography.

Please find here the link to the EUSOBI Position Paper: https://pubmed.ncbi.nlm.nih.gov/27807699/

Additionally, this could be also helpful: https://www.sciencedirect.com/science/article/pii/S0960977620300606?via%3Dihub

answered by P. Clauser

There are specific tools to assess the risk of developing breast cancer, which do not only consider the family history of breast cancer or other risk factors. It is important to follow as much as possible well established guidelines and recommendations when defining a woman’s risk level.

Information on how to classify a patient as FH patient can be found here, according with NICE guidelines: https://cks.nice.org.uk/topics/breast-cancer-managing-fh/management/breast-cancer-managing-fh/

Starting age is influenced by different factors. Information from the High Risk screening programme in UK can be found here:
https://www.gov.uk/government/publications/breast-screening-higher-risk-women-surveillance-protocols

answered by E. Giannotti & P. Clauser

YES:
If surgical candidate with either dense breast/ suspicion of multifocality/-centricity on conventional imaging (with equivocal findings on conventional imaging).
If neoadjuvant chemotherapy planned
If not surgical candidate and neoendocrine treatment planned if MRI is tolerated (otherwise US)

NO:
Bilateral mastectomy planned
Non-dense breast with unifocal cancer/ no suspicion of multifocality/-centricity on conventional imaging
Obviously, in case of contraindications to MRI or contrast agent administration

answered by R. Mann, K. Pinker-Domenig and P. Clauser

In case of a focus (enhancing lesion < 5 mm), it is important to make sure that there is no correlate in the pre-contrast and in the T2-weighted images that might help with further characterization towards a small suspicious mass or benign lesion. In the absence of a correlate on T1 and T2 weighted sequence, the symmetry should be evaluated: diffuse, symmetric foci  are in general expression of diffuse benign changes in the breast.

In case of a single focus or focal non mass enhancement, there is only a little number of findings specific for a benign diagnosis. Small intralesional cysts, high ADC values and homogeneous and persistent enhancement curves suggest a benign finding. In the clinical context of cancer staging, it is very important whether the additional finding may be oncologically relevant (thus, discuss the impact on the therapy with the team). In many cases, such findings represent B3 lesions which e.g. in case of adjuvant radiation therapy and antihormonal therapy may be oncologically well treated without dedicated surgery. It is a difficult and case-by-case decision to biopsy such lesions or not (thus, all imaging and clinical information should be considered).

answered by P. Baltzer and P. Clauser

Linear enhancement is most frequently intraductal in origin, and consequently follows the ductal structure of the breast.

The term stippled however does no longer exist, as stippled enhancement has been grouped with background parenchymal enhancement.

In the area of non-mass enhancement you might encounter a focal area of enhancement or regional enhancement that does not conform to a ductal tree structure. These may still be worrysome as they may be caused by diffusely growing infiltrative tumors (e.g. lobulars). In most of the cases you will find more features pointing in the direction of cancer (i.e. exceptionally rapid enhancement and wash-out, edema, low adc values, etc.)

answered by R.M. Mann